The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2. ODBG-P-RVn showed 20-fold greater antiviral activity than GS-441524 and had near-equivalent activity to remdesivir in primary-like human small airway epithelial cells. Our results warrant investigation of ODBG-P-RVn efficacy in vivo.
All Keywords
【저자키워드】 SARS-CoV-2, Remdesivir, respiratory viruses, Antiviral agents, GS-441524, VERO E6 cells, Nipah virus, Ebola virus, GS-5734, Hemorrhagic fever virus, paramyxovirus, HUH7 cells, henipavirus, filovirus, remdesivir nucleoside, lipid prodrugs, ODBG, NCI-H358 cells, human telomerase reverse-transcriptase (hTERT) immortalized microvascular endothelial cells (TIME), human small airway epithelial cells (HSAEC1-KT),
【저자키워드】 SARS-CoV-2, Remdesivir, respiratory viruses, Antiviral agents, GS-441524, VERO E6 cells, Nipah virus, Ebola virus, GS-5734, Hemorrhagic fever virus, paramyxovirus, HUH7 cells, henipavirus, filovirus, remdesivir nucleoside, lipid prodrugs, ODBG, NCI-H358 cells, human telomerase reverse-transcriptase (hTERT) immortalized microvascular endothelial cells (TIME), human small airway epithelial cells (HSAEC1-KT),